Aerosolized Plus Intravenous Polymyxin B Versus Colistin in the Treatment of Pandrug-Resistant Klebsiella Pneumonia-mediated Ventilator-Associated Pneumonia: A Retrospective Cohort Study in Bangladesh

Hasan, Md Jahidul; Sumi, Chandra Datta; Huq, Shihan Mahmud Redwanul; Anam, Ahmad Mursel; Rabbani, Raihan

doi:10.2478/jccm-2023-0012

Abstract

Background

Pandrug-resistant Klebsiella pneumoniae ventilator associated pneumonia (VAP) is associated with high rate of mortality in intensive care unit (ICU) and has been recognized as a difficult-to-treat infection worldwide. Polymyxin B or colistin-based combination therapies are frequently used worldwide though microbial eradication rate is not promising.

Aim

The aim of this study is to compare the clinical outcome of intravenous with aerosolized polymyxin B versus colistin in the treatment of pandrug-resistant K. pneumoniae VAP.

Methods

This retrospective cohort study was conducted on 222 mechanically ventilated patients admitted from May 11, 2019 to October 19, 2020. K. pneumoniae isolates were resistant to all available antibiotics, including polymyxins in culture sensitivity tests. As treatment, polymyxin B and colistin was administered in intravenous and aerosolized form concurrently twice daily in 106 patients and 116 patients in PMB and CLN group, respectively for 14 days. Survival rate, safety, and clinical outcomes were compared among the groups. The Cox proportional-hazard model was performed to calculate hazard ratio (HR) with 95% confidence intervals (CI).

Results

Patients in PMB group showed more microbial eradication than the patients CLN group [68.1% (n=116)/83% (n=106), respectively; P <0.05). The median day of intubation and ICU stay in PMB group was shorter than that in CLN group [10 (IQR: 9-12.25) vs. 14 (IQR: 11-19), P <0.05; 12 (IQR: 10-14) vs. 15 (IQR: 9-18.5), P=0.072, respectively] with reduced 60-day all-cause mortality rate [15% (n=106) vs. 21.55% (n=116)]. Polymyxin B improved survival compared to colistin (multivariate HR: 0.662; 95% CI=0.359-1.222, P=0.195).

Conclusions

Concurrent administration of intravenous and aerosolized polymyxin B in patients with pandrug-resistant K. pneumoniae-associated VAP revealed better microbial eradication, reduced the length of intubation and ICU stay, and improved survival rate compared to colistin.

References

1. Zimlichman E, Henderson D, Tamir O, Franz C, Song P, Yamin CK, et al. Health care-associated infections: a meta-analysis of costs and financial impact on the US health care system. JAMA Intern Med 2013;173(22):2039–46.
Search in Google Scholar Back to article
2. Wu D, Wu C, Zhang S, Zhong Y. Risk factors of ventilator-associated pneumonia in critically iii patients. Front Pharmacol 2019;10:482.
Search in Google Scholar Back to article
3. Kalil AC, Metersky ML, Klompas M, Muscedere J, Sweeney DA, Palmer L B, et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the infectious diseases society of america and the american thoracic society. Clin Infect Dis 2016;63:e61–e111.
Search in Google Scholar Back to article
4. Martin-Loeches I, Rodriguez AH, Torres A. New guidelines for hospital-acquired pneumonia/ventilator-associated pneumonia. Curr Opin Crit Care 2018;24:347–52.
Search in Google Scholar Back to article
5. Ding C, Zhang Y, Yang Z, Wang J, Jin A, Wang W, et al. Incidence, temporal trend and factors associated with ventilator-associated pneumonia in mainland China: a systematic review and meta-analysis. BMC Infect Dis 2017;17(1):468.
Search in Google Scholar Back to article
6. Karim MR, Mayedah R, Cader F A. Ventilator-associated pneumonia in Coronary Care Unit of a tertiary level hospital in Bangladesh: causative organisms and pattern of antibiotic sensitivity. Bangladesh Critical Care Journal 2019;7(2):73–6.
Search in Google Scholar Back to article
7. Pontikis K, Karaiskos I, Bastani S, Dimopoulos G, Kalogirou M, Katsiari M, et al. Outcomes of critically ill intensive care unit patients treated with fosfomycin for infections due topandrug-resistant and extensively drug-resistant carbapenemase-producing Gram-negative bacteria. Int J Antimicrob Agents 2014;43(1):52–9.
Search in Google Scholar Back to article
8. Juan CH, Fang SY, Chou CH, Tsai TY, Lin YT. Clinical characteristics of patients with pneumonia caused by Klebsiella pneumoniae in Taiwan and prevalence of antimicrobial-resistant and hypervirulent strains: a retrospective study. Antimicrob Resist Infect Control 2020;9(1):4.
Search in Google Scholar Back to article
9. Navon-Venezia S, Kondratyeva K, Carattoli A. Klebsiella pneumoniae: a major worldwide source and shuttle for antibiotic resistance. FEMS Microbiol Rev 2017;41:252–75.
Search in Google Scholar Back to article
10. Tuon FF, Graf ME, Merlini A, Rocha JL, Stallbaum S, Arend LN, et al. Risk factors for mortality in patients with ventilator-associated pneumonia caused by carbapenem-resistant Enterobacteriaceae. Braz J Infect Dis 2017;21(1):1–6.
Search in Google Scholar Back to article
11. Capone A, Giannella M, Fortini D, Giordano A, Meledandri M, Ballardini M, et al. High rate of colistin resistance among patients with carbapenem-resistant Klebsiella pneumoniae infection accounts for an excess of mortality. Clin Microbiol Infect 2013;19(1):E23–E30.
Search in Google Scholar Back to article
12. Tran TB, Velkov T, Nation RL, Forrest A, Tsuji BT, Bergen PJ, et al. Pharmacokinetics/pharmacodynamics of colistin and polymyxin B: are we there yet? Int J Antimicrob Agents 2016;48(6):592–7.
Search in Google Scholar Back to article
13. Hasan MJ. Polymyxins nebulization over intravenous injection: pharmacokinetics and pharmacodynamics-based therapeutic evaluation. J Pharm Res Int 2019;25(4):1–10.
Search in Google Scholar Back to article
14. Hasan MJ, Rabbani R, Anam AM, Santini A, Huq SMR. The Susceptibility of MDR-K. pneumoniae to polymyxin b plus its nebulised form versus polymyxin b alone in critically ill south asian patients. J Crit Care Med (Targu Mures) 2021;7(1):28–36.
Search in Google Scholar Back to article
15. Standards of clinical and laboratory standards institute (CLSI). Performance Standards for Antimicrobial Susceptibility Testing. 30th ed. CLSI supplement M100. Wayne, PA: Clinical and Laboratory Standards Institute; 2020. https://clsi.org/media/3481/m100ed30_sample.pdf Available at. (accessed 20 April 2021)
Search in Google Scholar Back to article
16. EUCAST: European Committee on Antimicrobial Susceptibility Testing breakpoint tables for interpretation of MICs and zone diameters, Eleventh Version. 2021. Available at: https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Breakpoint_tables/v_11.0_Breakpoint_Tables.pdf (accessed 20 April 2021).
Search in Google Scholar Back to article
17. Fernando SM, Tran A, Cheng W, Klompas M, Kyeremanteng K, Mehta S, et al. Diagnosis of ventilator-associated pneumonia in critically ill adult patients-a systematic review and meta-analysis. Intensive Care Med 2020;46(6):1170–9.
Search in Google Scholar Back to article
18. Leuppi-Taegtmeyer AB, Decosterd L, Osthoff M, Mueller NJ, Buclin T, Corti N. Multicenter Population Pharmacokinetic Study of Colistimethate Sodium and Colistin Dosed as in Normal Renal Function in Patients on Continuous Renal Replacement Therapy. Antimicrob Agents Chemother 2019;63(2):e01957–18.
Search in Google Scholar Back to article
19. Lin YW, Zhou Q, Onufrak NJ, Wirth V, Chen K, Wang J, et al. Aerosolized polymyxin b for treatment of respiratory tract infections: determination of pharmacokinetic-pharmacodynamic indices for aerosolized polymyxin b against Pseudomonas aeruginosa in a mouse lung infection model. Antimicrob Agents Chemother 2017;61(8):e00211–17.
Search in Google Scholar Back to article
20. Hasan M J, Rabbani R, Bachar S C. Therapeutic specification of the last resort polymyxins: an intelligent approach, Int J Infect 2019;6(4):e96828.
Search in Google Scholar Back to article
21. Sarda C, Fazal F, Rello J. Management of ventilator-associated pneumonia (VAP) caused by resistant gram-negative bacteria: which is the best strategy to treat? Expert Rev Respir Med 2019;13(8):787–98.
Search in Google Scholar Back to article
22. Yapa SWS, Li J, Patel K, Wilson JW, Dooley MJ, George J, et al. Pulmonary and systemic pharmacokinetics of inhaled and intravenous colistin methanesulfonate in cystic fibrosis patients: targeting advantage of inhalational administration. Antimicrob Agents Chemother 2014;58(5):2570–9.
Search in Google Scholar Back to article
23. Imberti R, Cusato M, Villani P, Carnevale L, Iotti GA, Langer M, et al. Steady-state pharmacokinetics and BAL concentration of colistin in critically ill patients after IV colistin methanesulfonate administration. Chest 2010;138(6):1333–9.
Search in Google Scholar Back to article
24. Athanassa ZE, Markantonis SL, Fousteri MZ, Myrianthefs PM, Boutzouka EG, Tsakris Aet al. Pharmacokinetics of inhaled colistimethate sodium (CMS) in mechanically ventilated critically ill patients. Intensive Care Med 2012;38(11):1779–86.
Search in Google Scholar Back to article
25. Lin YW, Zhou Q, Onufrak NJ, Wirth V, Chen K, Wang J, et al. Aerosolized Polymyxin B for Treatment of Respiratory Tract Infections: Determination of Pharmacokinetic-Pharmacodynamic Indices for Aerosolized Polymyxin B against Pseudomonas aeruginosa in a Mouse Lung Infection Model. Antimicrob Agents Chemother 2017;61(8):e00211–17.
Search in Google Scholar Back to article
26. Xu Q, Xu T, Zhuang Y, Liu X, Li Y, Chen Y. In Vivo Development of Polymyxin B Resistance in Klebsiella pneumoniae owing to a 42 bp Deletion in the Sequence of phoQ. Biomed Res Int. 2020;2020:5868479.
Search in Google Scholar Back to article